FDA approves Hibsago, the first antisense drug for chronic hepatitis B

The FDA approves Hibsago, the first antisense drug for chronic hepatitis B, the Philips Lumify ultrasound correction becomes a Class I recall after four deaths, and a Maryland lab owner is convicted of Medicare fraud.